Truncated thioredoxin peptides serves as an efficient fusion tag for production of proinsulin.
Several recombinant proteins of therapeutic value such as Proinsulin have long been produced from engineered E. coli strains. For the recombinant products to be produced at a commercially viable scale, selection of appropriate fusion tags would play a major role. Production of recombinant proteins with well-known fusion tags have posed problems associated with the high molecular weight, as these contribute to 50 - 80% of total expressed protein. The ratio of the recombinant protein to the fusion tags play a major role in enhancing the expression levels and determining the recovery percentage of small polypeptides such as proinsulin. Expressing proinsulin at a commercial scale needs fusion tags which will not only enhance the expression levels but also increase the protein stability. Furthermore, production of the heterologous recombinant protein in a soluble form will significantly avoid the cost involved in solubilizing inclusion bodies. Here we report that the usage of thioredoxin as a fusion tag helped enhancing the expression of proinsulin. To reduce the molar ratio of fusion tag TRX: Proinsulin, TRX tag was initially truncated into 6 fragments, and was further truncated into additional 5 tags ranging from 10 - 20 amino acids. Among the various truncated forms, FCTRX (1-15) sequence was selected as an ideal fusion tag. This tag can possibly be used as a fusion partner with any other recombinant proteins or peptides to be expressed in commercial scale.